<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Medtronic begins international sales of semi-closed loop Paradigm Veo diabetes device</title>
	<atom:link href="http://www.medcitynews.com/2009/09/medtronic-begins-international-sales-semi-closed-loop-paradigm-veo-diabetes-device/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.medcitynews.com/2009/09/medtronic-begins-international-sales-semi-closed-loop-paradigm-veo-diabetes-device/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=medtronic-begins-international-sales-semi-closed-loop-paradigm-veo-diabetes-device</link>
	<description>MedCity News</description>
	<lastBuildDate>Sat, 11 Feb 2012 15:17:29 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
	<item>
		<title>By: Medtronic sued for patent infringement on glucose-monitoring system : MedCity News</title>
		<link>http://www.medcitynews.com/2009/09/medtronic-begins-international-sales-semi-closed-loop-paradigm-veo-diabetes-device/comment-page-1/#comment-42322</link>
		<dc:creator>Medtronic sued for patent infringement on glucose-monitoring system : MedCity News</dc:creator>
		<pubDate>Thu, 10 Dec 2009 19:45:25 +0000</pubDate>
		<guid isPermaLink="false">http://www.medcitynews.com/?p=11008#comment-42322</guid>
		<description>[...] Medtronic in July extricated itself from a series of stent-related patent suits after a $400 million settlement with Abbott Laboratories. Diabetes is considered one of the long-term, high-growth segments for Medtronic, which is trying to develop an artificial pancreas system. [...]</description>
		<content:encoded><![CDATA[<p>[...] Medtronic in July extricated itself from a series of stent-related patent suits after a $400 million settlement with Abbott Laboratories. Diabetes is considered one of the long-term, high-growth segments for Medtronic, which is trying to develop an artificial pancreas system. [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Minified using disk
Page Caching using disk (enhanced)

Served from: www.medcitynews.com @ 2012-02-13 08:13:42 -->
